title: [The safety and effectiveness of once daily detemir in patients with type 2 diabetes previously failing oral agents: the Chinese cohort from SOLVE(TM) observational study].
abstract: OBJECTIVE
  Study of Once-daily LeVEmir(®) (SOLVE(TM)) was a 24-week international observational study to evaluate the safety and effectiveness of initiating once-daily insulin detemir (Levemir) as add-on therapy in patients with type 2 diabetes mellitus (T2DM) who failed treatment of oral anti-diabetic drugs (OAD).
  
  
  METHODS
  The present study was derived from the data of Chinese cohort. A total of 3272 patients with T2DM failing OAD were enrolled in the study. Determir were prescribed to the patients by the decision of the physician. Clinical data were collected at baseline, week 12 and week 24 to evaluate the safety and effectiveness of detemir.
  
  
  RESULTS
  The age of the patients was (56.2 ± 10.8) years with a diabetes duration of (7.1 ± 5.2) years. Their BMI was (25.3 ± 3.3) kg/m(2). No patient experienced any major or nocturnal hypoglycaemic event during the study. After 24 weeks of treatment, the glycosylated hemoglobin A1c (HbA1c) decreased from (8.33 ± 1.69)% to (7.16 ± 1.18)% with a mean change of -1.17%, the fasting plasma glucose decreased from (9.52 ± 2.59) mmol/L to (6.84 ± 1.42) mmol/L with a mean change of -2.7 mmol/L, and the 7-point blood glucose profile improved overall. Totally 49.1% of patients achieved HbA1c < 7%. The mean body weight decreased by 0.15 kg.
  
  
  CONCLUSIONS
  Insulin detemir administered once daily as add-on therapy in patients with T2DM failing OAD regimen significantly reduces the risk of major hypoglycemia, improves glycemic control, increases the percentage of patients achieving treatment target with neutral effect on body weight.
authors.affiliation: Department of Endocrinology, Chinese PLA General Hospital, Beijing, China. panchy301@yahoo.com.cn
authors.forename: Chang-yu
authors.initials: CY
authors.lastname: Pan
authors.forename: Li-nong
authors.initials: LN
authors.lastname: Ji
authors.forename: Ju-ming
authors.initials: JM
authors.lastname: Lu
authors.forename: Wen-ying
authors.initials: WY
authors.lastname: Yang
authors.forename: Zhi-guang
authors.initials: ZG
authors.lastname: Zhou
authors.forename: Da-jin
authors.initials: DJ
authors.lastname: Zou
authors.forename: Qiu-he
authors.initials: QH
authors.lastname: Ji
authors.forename: Ping
authors.initials: P
authors.lastname: Han
authors.forename: Jie
authors.initials: J
authors.lastname: Liu
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.forename: Ben-li
authors.initials: BL
authors.lastname: Su
authors.forename: Yan-bing
authors.initials: YB
authors.lastname: Li
authors.forename: Zheng-nan
authors.initials: ZN
authors.lastname: Gao
authors.forename: Peng-hua
authors.initials: PH
authors.lastname: Wang
authors.forename: Shi-nan
authors.initials: SN
authors.lastname: Yin
authors.forename: Yan-hu
authors.initials: YH
authors.lastname: Dong
authors.forename: Tao
authors.initials: T
authors.lastname: Yang
authors.forename: Kan
authors.initials: K
authors.lastname: Sun
authors.forename: Hong
authors.initials: H
authors.lastname: Li
authors.forename: Xu
authors.initials: X
authors.lastname: Hong
authors.forename: Jing
authors.initials: J
authors.lastname: Lin
authors.forename: Jing-mei
authors.initials: JM
authors.lastname: Shi
authors.forename: Xiao-jie
authors.initials: XJ
authors.lastname: Yang
authors.forename: Hui
authors.initials: H
authors.lastname: Fang
authors.forename: Xiao-dong
authors.initials: XD
authors.lastname: Yan
mesh_terms: D000368:Aged; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D000069057:Insulin Detemir; D049528:Insulin, Long-Acting / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D007004:Hypoglycemic Agents; D049528:Insulin, Long-Acting; D000069057:Insulin Detemir